Drugs

, Volume 67, Issue 10, pp 1429–1440 | Cite as

Hereditary and Acquired Antithrombin Deficiency

Epidemiology, Pathogenesis and Treatment Options
Review Article

Abstract

Antithrombin is a glycoprotein critical to the regulation of coagulation. Its primary action is the inhibition of the activated coagulation factors IIa (thrombin) and Xa. In addition there is growing evidence to suggest that antithrombin also plays a role in the inhibition of inflammation within the environment of the vascular endothelium. Reduced plasma antithrombin may result from congenital deficiency or arise secondarily from a range of disorders such as liver dysfunction, premature infancy and sepsis, or as a result of interventions such as major surgery or cardiopulmonary bypass.

Congenital antithrombin deficiency is the most clinically important of the inherited thrombophilias resulting in thrombosis in the majority of those affected. The challenge in managing these patients is preventing potentially life-threatening thrombosis, while minimising the equally significant risk of haemorrhage associated with long-term anticoagulation. This is achieved in the first instance by identifying high-risk episodes such as surgery, immobility and pregnancy for which prophylactic anticoagulation can be used in the short term. Prophylaxis for such periods is best provided by the use of low molecular weight heparin (LMWH) with substitution by or addition of antithrombin concentrate in particularly high-risk circumstances. In the case of pregnancy, antithrombin concentrate is often used around the time of birth when LMWH may increase the risk of post-partum haemorrhage. As patients with congenital antithrombin deficiency get older so their thrombotic risk gradually increases and for many patients long-term anticoagulation becomes unavoidable because of recurrent episodes of venous thromboembolism.

There has been much interest in the role of antithrombin deficiency in the setting of sepsis and the critically ill patient where there is a clear correlation between severity of illness and degree of antithrombin reduction. It is not clear yet, however, to what extent the depletion of antithrombin affects the clinical condition of such patients. A number of trials have investigated the use of antithrombin as a treatment in the intensive care setting with the overall conclusion being that there is some benefit to its use but only if large supra-physiological doses are used. It has also become clear that the concurrent use of any form of heparin removes whatever benefit may be derived from antithrombin treatment in this setting. Until recently, antithrombin replacement was only available as a pooled plasma-derived product, which despite effective viral inactivation still carries an uncertain risk of transfusion transmitted infection. A recombinant antithrombin product now under investigation, and recently licensed in Europe, may provide a useful alternative treatment option.

References

  1. 1.
    Hunt LT, Dayhoff MO. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem Biophys Res Commun 1980 Jul 31; 95(2): 864–71PubMedCrossRefGoogle Scholar
  2. 2.
    Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombindeficient mice. Blood 2002 Apr 1; 99(7): 2455–8PubMedCrossRefGoogle Scholar
  3. 3.
    Lane DA, Kunz G, Olds RJ, et al. Molecular genetics of antithrombin deficiency. Blood Rev 1996 Jun; 10(2): 59–74PubMedCrossRefGoogle Scholar
  4. 4.
    Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002 Nov; 126(11): 1326–36PubMedGoogle Scholar
  5. 5.
    Walker CPR, Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth 2002 Jun; 88(6): 848–63PubMedCrossRefGoogle Scholar
  6. 6.
    Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24(1): 19–25PubMedCrossRefGoogle Scholar
  7. 7.
    Wiedermann CJ, Romisch J. The anti-inflammatory actions of antithrombin: a review. Acta Med Austriaca 2002; 29(3): 89–92PubMedCrossRefGoogle Scholar
  8. 8.
    White B, Perry D. Acquired antithrombin deficiency in sepsis. Br J Haematol 2001 Jan; 112(1): 26–31PubMedCrossRefGoogle Scholar
  9. 9.
    Egeberg O. Inherited fibrinogen abnormality causing thrombophilia. Thromb Diath Haemorrh 1967 Feb 28; 17(1–2): 176–87PubMedGoogle Scholar
  10. 10.
    Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997 Jan; 77(1): 197–211PubMedGoogle Scholar
  11. 11.
    Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency: incidence and clinical features. Am J Med 1989 Sep 11; 87(3B): 34–8SCrossRefGoogle Scholar
  12. 12.
    Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975 Jan 16; 292(3): 146–51PubMedCrossRefGoogle Scholar
  13. 13.
    Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994 May; 87(1): 106–12PubMedCrossRefGoogle Scholar
  14. 14.
    Harper PL, Luddington RJ, Daly M, et al. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 1991 Mar; 77(3): 360–4PubMedCrossRefGoogle Scholar
  15. 15.
    Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997 Mar; 77(3): 444–51PubMedGoogle Scholar
  16. 16.
    McColl M, Tait RC, Walker ID, et al. Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 1996 Oct; 7(7): 689–94PubMedCrossRefGoogle Scholar
  17. 17.
    Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998 Oct 1; 92(7): 2353–8PubMedGoogle Scholar
  18. 18.
    Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987 Dec 18; 58(4): 1094PubMedGoogle Scholar
  19. 19.
    Bushman JE, Palmieri D, Whinna HC, et al. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000 Jul; 24(7): 559–65PubMedCrossRefGoogle Scholar
  20. 20.
    Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998 Jun; 79(6): 1166–70PubMedGoogle Scholar
  21. 21.
    Wickstrom K, Edelstam G, Lowbeer CH, et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64(1): 31–40PubMedCrossRefGoogle Scholar
  22. 22.
    Morikawa M, Yamada T, Kataoka S, et al. Changes in antithrombin activity and platelet counts in the late stage of twin and triplet pregnancies. Semin Thromb Hemost 2005 Jun; 31(3): 290–6PubMedCrossRefGoogle Scholar
  23. 23.
    Tait RC, Walker ID, Islam SI, et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993 Jul; 84(3): 476–80PubMedCrossRefGoogle Scholar
  24. 24.
    Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002 Oct 1; 100(7): 2403–5PubMedCrossRefGoogle Scholar
  25. 25.
    Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. Crit Rev Clin Lab Sci 2006; 43(3): 249–90PubMedCrossRefGoogle Scholar
  26. 26.
    van Boven HH, Vandenbroucke JP, Westendorp RG, et al. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997 Mar; 77(3): 452–5PubMedGoogle Scholar
  27. 27.
    Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999 Dec 1; 94(11): 3702–6PubMedGoogle Scholar
  28. 28.
    Demers C, Ginsberg JS, Hirsh J, et al. Thrombosis in antithrombin-III-deficient persons: report of a large kindred and literature review. Ann Intern Med 1992 May 1; 116(9): 754–61PubMedGoogle Scholar
  29. 29.
    Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006 Jan; 132(2): 171–96PubMedCrossRefGoogle Scholar
  30. 30.
    McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997 Oct; 78(4): 1183–8PubMedGoogle Scholar
  31. 31.
    Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996 Oct 5; 348(9032): 913–6PubMedCrossRefGoogle Scholar
  32. 32.
    Krabbendam I, Franx A, Bots ML, et al. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2005 Feb 1; 118(2): 143–53PubMedCrossRefGoogle Scholar
  33. 33.
    Martinez MA, Pena JM, Fernandez A, et al. Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha. Crit Care Med 1999 Jul; 27(7): 1303–8PubMedCrossRefGoogle Scholar
  34. 34.
    Kessler CM, Tang Z, Jacobs HM, et al. The suprapharmacologic dosing of antithrombin concentrate for Staphyiococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997 Jun 15; 89(12): 4393–401PubMedGoogle Scholar
  35. 35.
    Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000 Feb 15; 95(4): 1117–23PubMedGoogle Scholar
  36. 36.
    Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003 Jan 25; 109(2–3): 73–81PubMedCrossRefGoogle Scholar
  37. 37.
    Paternoster D, Stella A, Simioni P, et al. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet 1994 Dec; 47(3): 215–21PubMedCrossRefGoogle Scholar
  38. 38.
    Sayin M, Varol FG, Sayin NC. Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy. Eur J Obstet Gynecol Reprod Biol 2005 Dec 1; 123(2): 183–7PubMedCrossRefGoogle Scholar
  39. 39.
    Levy JH, Despotis GJ, Szlam F, et al. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002 May; 96(5): 1095–102PubMedCrossRefGoogle Scholar
  40. 40.
    Ranucci M, Ditta A, Boncilli A, et al. Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass. Perfusion 2004 Jan; 19(1): 47–52PubMedCrossRefGoogle Scholar
  41. 41.
    Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996 Jan; 82(1): 13–21PubMedGoogle Scholar
  42. 42.
    Ranucci M, Frigiola A, Menicanti L, et al. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005 Feb; 33(2): 355–60PubMedCrossRefGoogle Scholar
  43. 43.
    Haemostasis and Thrombosis Task Force BCfSiH. Investigation and management of heritable thrombophilia. Br J Haematol 2001 Sep; 114(3): 512–28CrossRefGoogle Scholar
  44. 44.
    Menache D, O’Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990 Jan 1; 75(1): 33–9Google Scholar
  45. 45.
    Lechner K, Kyrle PA. Antithrombin III concentrates: are they clinically useful? Thromb Haemost 1995 Mar; 73(3): 340–8PubMedGoogle Scholar
  46. 46.
    Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003 Mar; 43(3): 390–4PubMedCrossRefGoogle Scholar
  47. 47.
    Bauer KA. Management of thrombophilia. J Thromb Haemost 2003 Jul; 1(7): 1429–34PubMedCrossRefGoogle Scholar
  48. 48.
    Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005 Sep; 25(9): 1992–7PubMedCrossRefGoogle Scholar
  49. 49.
    Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 627–44SCrossRefGoogle Scholar
  50. 50.
    Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005 Jul 15; 106(2): 401–7PubMedCrossRefGoogle Scholar
  51. 51.
    McColl MD, Greer IA. Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy. Curr Opin Pulm Med 2004 Sep; 10(5): 371–5PubMedCrossRefGoogle Scholar
  52. 52.
    Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14(2): 127–41PubMedCrossRefGoogle Scholar
  53. 53.
    Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998 Jul; 24(7): 663–72PubMedCrossRefGoogle Scholar
  54. 54.
    Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial [erratum appears in JAMA 2002 Jan 9; 287 (2): 192]. JAMA 2001 Oct 17; 286(15): 1869–78PubMedCrossRefGoogle Scholar
  55. 55.
    Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006 Feb; 34(2): 285–92PubMedCrossRefGoogle Scholar
  56. 56.
    Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006 Jan; 4(1): 90–7PubMedCrossRefGoogle Scholar
  57. 57.
    Minneci PC, Deans KJ, Cui X, et al. Antithrombotic therapies for sepsis: a need for more studies. Crit Care Med 2006 Feb; 34(2): 538–41PubMedCrossRefGoogle Scholar
  58. 58.
    Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002 Feb; 123(2): 213–7PubMedCrossRefGoogle Scholar
  59. 59.
    Williams MR, D’Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000 Sep; 70(3): 873–7PubMedCrossRefGoogle Scholar
  60. 60.
    Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005 Jul; 130(1): 107–13PubMedCrossRefGoogle Scholar
  61. 61.
    Nomura F, Ihara A, Yoshitatsu M, et al. Relationship between coagulation cascade, cytokine, adhesion molecule and aortic aneurysm. Eur J Cardiothorac Surg 2003 Jun; 23(6): 1034–8PubMedCrossRefGoogle Scholar
  62. 62.
    Nishiyama T. Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery. Anesth Analg 2006 Apr; 102(4): 1007–11PubMedCrossRefGoogle Scholar
  63. 63.
    Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving 1-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003 Aug; 90(2): 235–44Google Scholar
  64. 64.
    Matsuzaki A, Suminoe A, Hara T. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase. Pediatr Hematol Oncol 2002 Dec; 19(8): 601–3PubMedCrossRefGoogle Scholar
  65. 65.
    Morris JD, Harris RE, Hashmi R, et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997 Nov; 20(10): 871–8PubMedCrossRefGoogle Scholar
  66. 66.
    Schmidt B, Gillie P, Mitchell L, et al. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998 Aug; 158(2): 470–6PubMedGoogle Scholar
  67. 67.
    Fulia F, Cordaro S, Meo P, et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants? Biol Neonate 2003; 83(1): 1–5PubMedCrossRefGoogle Scholar
  68. 68.
    Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998 Jun 15; 91(12): 4561–71PubMedGoogle Scholar
  69. 69.
    Lu W, Mant T, Levy JH, et al. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg 2000 Mar; 90(3): 531–4PubMedCrossRefGoogle Scholar
  70. 70.
    Makris M. Safety of antithrombin III concentrate. Blood 1990 Aug 1; 76(3): 649–50PubMedGoogle Scholar
  71. 71.
    Chang WS, Harper PL. Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Thromb Haemost 1997 Feb; 77(2): 323–8PubMedGoogle Scholar
  72. 72.
    De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996 May 1; 87(9): 3531–44PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of HaematologyGlasgow Royal InfirmaryGlasgowUK

Personalised recommendations